Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®

Thea Pharma

Status: Enrolling

Conditions: Adherence to Glaucoma Therapy

Study type: Observational

Funder types: Industry

Identifiers

NCT07206628

LT9060-002

Details and patient eligibility

About

The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma already treated with IOP-lowering eye drops using connected device CONNECTDROP®

The main questions it aims to answer are:

• The mean annual adherence rate, defined as the percentage of the prescribed doses taken by the patient
• The adherence profile of each patient
• The association between the adherence profile, the objective adherence data and the clinical data.

Participants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (≥ 18 years old), man or woman
• Patient with a diagnosis of bilateral open angle glaucoma
• Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy.
• Patient willing to participate in the study
• Patient who consents for data collection in the frame of the study

Exclusion criteria

• Pregnant and/or lactating woman
• Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months)
• Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision

Trial design

200 participants in 1 patient group

Group receiving T9060 CONNECTDROP